

Company registration number: 438429

**Mid West Regional Drugs Task Force
Company Limited by Guarantee**

Financial statements

for the financial year ended 31 December 2023

**Mid West Regional Drugs Task Force
Company Limited by Guarantee**

Contents

	Page
Directors and other information	1
Directors report	2 - 3
Directors responsibilities statement	4
Independent auditor's report to the members	5 - 7
Income and expenditure account	8
Balance sheet	9
Statement of changes in funds	10
Notes to the financial statements	11 - 18

**Mid West Regional Drugs Task Force
Company limited by guarantee**

Directors and other information

Directors	Mick Lacey James Finn Maurice Quinlivan
Secretary	Ann Marie Carey
Registered Charity Number	20071875
CHY Number	18637
Company number	438429
Registered office	P.O. Box 486 Corporate House Mungret Street Limerick
Business address	P.O. Box 486 Corporate House Mungret Street Limerick
Auditor	FDC and Associates Ltd F.D.C. House Wellington Road Cork
Bankers	Bank of Ireland 125 O'Connell Street Limerick

**Mid West Regional Drugs Task Force
Company Limited by Guarantee**

Directors report

The directors present their annual report and the audited financial statements of the company for the financial year ended 31 December 2023.

Reference and Administrative Details

The company is a not for profit company with a registered office at P.O. Box 486, Corporate House, Limerick. The companies registered number is 438429.

Directors

The names of the persons who at any time during the financial year were directors of the company are:

Mick Lacey

James Finn

Maurice Quinlivan

Principal activities and objectives

The principal activity of the company during the year was to research, develop, implement and monitor a co-ordinated response to drug use at regional level. The directors are satisfied that the company continues to meet its objectives in this regard.

Achievements and performance

The MWRDTF continued to work in line with the National Drugs Strategy 2017-2025 'Reducing Harm Supporting Recovery'. The MWRDTF also continues to provide funding support to a range of services addressing the impact of substance misuse in the Mid-West region. The Forum also co-ordinates a range of networks and committees that have been set up under the various lead actions in the National Drugs Strategy. In addition the Forum co-ordinates a range of interventions and supports including seminars, training and the dissemination of information to name but a few. Some achievements include:

- Development of a new strategic plan for 2024-2026
- Redesign the forums website and have all drug and alcohol information more accessible to the public.
- Development of a community network and create a support system for new community reps for the forum.
- Continued growth of S.H.E.P. programme into Co. Limerick
- Research and development and the inclusion of peers to capture their experiences.
- Developing a community sharps instead of drug litter, as we continue to reduce the stigma associated with drugs.
- To support the roll out of care and case management across drug and alcohol services in the Mid-West Region.

Financial review

The Company is dependent on state funding. In common with many state funded companies there is the risk of reductions in the levels of funding due to the current downturn in economic activities. The directors are satisfied however that the company will be able to operate despite the cutbacks and that it can operate with the resources provided for the foreseeable future.

At the end of the year the company has assets of €129,735 (2022: €108,503) and liabilities of €70,188, (2022: €79,827). The net assets of the company have increased by €7,690 and the directors are satisfied with the level of retained funds at the year-end.

Reserves policy

The company's funds are restricted to the activities specified by the funder and are expected to be spent in the short term. The company does not have any investments and as a not for profit company does not envisage a situation whereby the company has more funds that is required to fund ongoing expenditure.

Structure, Governance and Management

**Mid West Regional Drugs Task Force
Company Limited by Guarantee**

Directors report

The company is a not for profit company limited by guarantee. The company does not have a share capital and consequently the liability of members is limited, subject to an undertaking by each member to contribute to the net assets or liabilities of the company on winding up such amounts as may be required not exceeding one Euro (€1) .

Management Structure. The company was established under a Constitution which established the objects and powers of the company and is governed under its Constitution and managed by a Board of Directors. The Board of Directors include some who live and or work in the local Community. The directors act in a voluntary capacity and do not receive any remuneration. The Board consists of a Chairperson, Vice Chairperson, Secretary and Committee. The company is managed by a full-time administrator. The management team have worked very hard over the past years building and developing on our aims and objectives. The management team meet on a regular basis to carry out and monitor progress on ongoing projects and services.

The company currently has four directors who meet on a quarterly basis and are responsible for the strategic direction of the company. At these meetings the board of directors are provided with the key performance and risk indicators. The administrator is responsible for ensuring that the company meets its long and short term aims and the day to day operations run smoothly.

The board held four meetings during 2023 with an average attendance of 80%.

Likely future developments

The directors are not expecting to make significant changes in the nature of the business in the near future.

Events after the end of the reporting period

There have been no significant events affecting the company since the year end.

Accounting records

The measures taken by the directors to secure compliance with the requirements of sections 281 to 285 of the Irish Generally Accepted Accounting Practice in Ireland with regard to the keeping of accounting records are the implementation of necessary policies and procedures for recording transactions, the employment of competent accounting personnel with appropriate expertise and the provision of adequate resources to the financial function. The accounting records of the company are located at P.O. Box 486, Corporate House, Mungret Street, Limerick..

Relevant audit information


In the case of each of the persons who are directors at the time this report is approved in accordance with section 332 of Irish Generally Accepted Accounting Practice in Ireland:


- so far as each director is aware, there is no relevant audit information of which the company's statutory auditors are unaware, and
- each director has taken all the steps that he or she ought to have taken as a director in order to make himself or herself aware of any relevant audit information and to establish that the company's statutory auditors are aware of that information.

Auditors

The auditors, F.D.C. and Associates Ltd, have expressed their willingness to continue in office in accordance with the provisions of Section 383(2) of the Companies Act 2014.

Approved by the board of directors on 11 April 2024 and signed on its behalf by:


Director: Mick Lacey


Director: James Finn

**Mid West Regional Drugs Task Force
Company Limited by Guarantee**

Directors responsibilities statement

The directors are responsible for preparing the directors report and the financial statements in accordance with applicable Irish law and regulations.


Irish company law requires the directors to prepare financial statements for each financial year, giving a true and fair view of the state of affairs of the Company. Under the law, the directors have elected to prepare the financial statements in accordance with the Irish Generally Accepted Accounting Practice in Ireland, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the Republic of Ireland' and Irish law. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Irish Generally Accepted Accounting Practice in Ireland.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and directors report comply with the Irish Generally Accepted Accounting Practice in Ireland and enable the financial statements to be audited. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

This statement was approved by the board on the 11 April 2024 and signed on its behalf by:


Mick Lacey
Director


James Finn
Director

Independent auditor's report to the members of Mid West Regional Drugs Task Force

Opinion

We have audited the financial statements of Mid West Regional Drugs Task Force, which comprise the balance sheet as at 31 December 2023, and the income statement, statement of changes in retained funds for the year then ended, and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable Irish law and Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland, applying Section 1A of the Standard.

In our opinion, the financial statements:

- give a true and fair view of the assets, liabilities and financial position of the company as at 31 December 2023 and of its profit for the year then ended;
- have been properly prepared in accordance with Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland, applying Section 1A of the Standard, and
- have been prepared in accordance with the requirements of the Companies Act 2014.

The purpose of our audit work and to whom we owe our responsibilities

This report is made solely to the company's members, as a body, in accordance with section 391 of the Companies Act 2014. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (Ireland) (ISAs (Ireland)) and applicable law. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the ethical requirements that are relevant to our audit of the financial statements in Ireland including the Irish Auditing and Accounting Supervisory Authority (IAASA) Ethical Standard and we have fulfilled our other responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

- Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Company's ability to continue as a going concern for a period of at least twelve months from the date when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

Independent auditor's report to the members of Mid West Regional Drugs Task Force

The directors are responsible for the other information. The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2014

Based solely on the work undertaken in the course of the audit, we report that:

- In our opinion, the information given in the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- In our opinion, the directors' report is consistent with the financial statements and has been prepared in accordance with the Companies Act 2014 and;
- We have obtained all the information and explanations which we consider necessary for the purposes of our audit.
- In our opinion the accounting records of the company were sufficient to permit the financial statements to be readily and properly audited and the financial statements are in agreement with the accounting records

Matter on which we are required to report by exception

In the light of our knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the directors' report.

The Companies Act 2014 requires us to report to you if, in our opinion, the disclosures of directors' remuneration and transactions required by sections 305 to 312 of the Act are not made. We have nothing to report in this regard.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

As explained more fully in the directors' responsibilities statement, management is responsible for the preparation of the financial statements in accordance with Irish law and FRS 102, the Financial Reporting Standard applicable in the UK and Republic of Ireland issued by the Financial Reporting Council and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

**Independent auditor's report to the members of
Mid West Regional Drugs Task Force**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern



Enda Ryan

For and on behalf of

FDC and Associates Ltd

Chartered Certified Accountants & Statutory Auditors

F.D.C. House

Wellington Road

Cork

Dated: 11 April 2024

11-04-2024.

**Mid West Regional Drugs Task Force
Company Limited by Guarantee**

**Income and expenditure account
Financial year ended 31 December 2023**

	Note	2023 €	2022 €
Income			
Donations and Grants		477,476	397,379
		<u>477,476</u>	<u>397,379</u>
Expenditure			
Direct charitable expenditure	5	464,819	442,587
Governance Costs		4,967	3,797
		<u>469,786</u>	<u>446,384</u>
Surplus/(deficit) for the financial year	7	7,690	(49,005)
		<u><u> </u></u>	<u><u> </u></u>

The company has no other recognised items of income and expenses other than the results for the financial year as set out above.

The notes on pages 11 to 18 form part of these financial statements.

**Mid West Regional Drugs Task Force
Company Limited by Guarantee**


**Balance sheet
As at 31 December 2023**

	Note	2023 €	€	2022 €	€
Fixed assets					
Tangible assets	8	2,902		2,771	
			2,902		2,771
Current assets					
Debtors	9	7,204		13,025	
Cash at bank and in hand		119,629		92,707	
		126,833		105,732	
Creditors: amounts falling due within one year	10	(83,648)		(70,237)	
Net current assets			43,185		35,495
Total assets less current liabilities			46,087		38,266
Creditors: amounts falling due after more than one year			(2,903)		(2,771)
Net assets			43,184		35,495
Funds:					
Restricted funds			43,184		35,495
Total funds			43,184		35,495

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

These financial statements were approved by the board of directors on 11 April 2024 and signed on behalf of the board by:


Mick Lacey
Director


James Finn
Director

The notes on pages 11 to 18 form part of these financial statements.

**Mid West Regional Drugs Task Force
Company Limited by Guarantee**

**Statement of changes in funds
Financial year ended 31 December 2023**

	Income and expenditure account €	Total €
At 1 January 2022	84,500	84,500
Surplus/(deficit) for the financial year	(49,005)	(49,005)
At 31 December 2022 and 1 January 2023	<u>35,494</u>	<u>35,494</u>
Surplus/(deficit) for the financial year	7,690	7,690
At 31 December 2023	<u><u>43,184</u></u>	<u><u>43,184</u></u>

**Mid West Regional Drugs Task Force
Company Limited by Guarantee**

**Notes to the financial statements
Financial year ended 31 December 2023**

1. General information

The company is a private company limited by guarantee, registered in Ireland. The address of the registered office is P.O. Box 486, Corporate House, Mungret Street, Limerick.

2. Accounting policies and measurement bases

Basis of preparation

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.

The financial statements are prepared in Euro, which is the functional currency of the entity.

Change in formats

The Directors have availed of the provisions of Section 291(5) of the Companies Act 2014 to use a format for the financial statements that better describes the activities of a company not trading for a profit. The main change being the replacement of the title "profit and loss" with the title "Income and Expenditure" and consequential changes in descriptions of certain items to be consistent with the descriptions appropriate to the not for profit sector.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. Judgements and estimates are continually evaluated and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Income

The company is funded mainly by grants from state agencies. These grants are treated as income in the period to which they relate. All other income is recognised in the period in which it is received.

Taxation

The company does not carry on any activity that would give rise to a Corporation Tax liability.

**Mid West Regional Drugs Task Force
Company Limited by Guarantee**

**Notes to the financial statements (continued)
Financial year ended 31 December 2023**

Tangible assets

Tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses.

Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.

Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Office equipment	- 25%	reducing balance
Computer equipment	- 25%	reducing balance

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.

Impairment

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date.

When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.

**Mid West Regional Drugs Task Force
Company Limited by Guarantee**

**Notes to the financial statements (continued)
Financial year ended 31 December 2023**

Government grants

Government grants are recognised at the fair value of the asset received or receivable. Grants are not recognised until there is reasonable assurance that the company will comply with the conditions attaching to them and the grants will be received.

Government grants are recognised using the accrual model.

Under the accrual model, government grants relating to revenue are recognised on a systematic basis over the periods in which the company recognises the related costs for which the grant is intended to compensate. Grants that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the entity with no future related costs are recognised in income in the period in which it becomes receivable.

Grants relating to assets are recognised in income on a systematic basis over the expected useful life of the asset. Where part of a grant relating to an asset is deferred, it is recognised as deferred income and not deducted from the carrying amount of the asset.

Financial instruments

A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Debt instruments are subsequently measured at amortised cost.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in surplus or deficit immediately.

Any reversals of impairment are recognised in surplus or deficit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.

3. Limited by guarantee

Mid West Regional Drugs Task Force is a company limited by guarantee having no share capital.

4. Operating surplus/(deficit)

Operating surplus/(deficit) is stated after charging/(crediting):

	2023	2022
	€	€
Depreciation of tangible assets	968	924
Fees payable for the audit of the financial statements	4,967	3,797
	<u> </u>	<u> </u>

**Mid West Regional Drugs Task Force
Company Limited by Guarantee**

**Notes to the financial statements (continued)
Financial year ended 31 December 2023**

5. Staff costs

The average number of persons employed by the company during the financial year was 4 (2022: 4).

The aggregate payroll costs incurred during the financial year were:

	2023	2022
	€	€
Wages and salaries	177,174	150,013
Social insurance costs	19,502	16,559
	<u>196,676</u>	<u>166,572</u>

6. Directors remuneration

The directors act in a voluntary capacity and do not receive any remuneration.

7. Appropriations of income and expenditure account

	2023	2022
	€	€
At the start of the financial year	35,494	84,500
Surplus/(deficit) for the financial year	7,690	(49,005)
At the end of the financial year	<u>43,184</u>	<u>35,495</u>

8. Tangible assets

	Computer equipment	Office equipment	Total
	€	€	€
Cost			
At 1 January 2023	24,101	3,076	27,177
Additions	1,100	-	1,100
At 31 December 2023	<u>25,201</u>	<u>3,076</u>	<u>28,277</u>
Depreciation			
At 1 January 2023	21,695	2,712	24,407
Charge for the financial year	877	91	968
At 31 December 2023	<u>22,572</u>	<u>2,803</u>	<u>25,375</u>
Carrying amount			
At 31 December 2023	<u>2,629</u>	<u>273</u>	<u>2,902</u>
At 31 December 2022	<u>2,406</u>	<u>364</u>	<u>2,770</u>

**Mid West Regional Drugs Task Force
Company Limited by Guarantee**

**Notes to the financial statements (continued)
Financial year ended 31 December 2023**

9. Debtors

	2023	2022
	€	€
Accrued income	7,204	13,025
	<u>7,204</u>	<u>13,025</u>

10. Creditors: amounts falling due within one year

	2023	2022
	€	€
PAYE and social welfare	16,028	11,598
Accruals	60,923	13,172
Deferred income	6,967	45,467
	<u>83,648</u>	<u>70,237</u>

**Mid West Regional Drugs Task Force
Company Limited by Guarantee**

**Notes to the financial statements (continued)
Financial year ended 31 December 2023**

11 State Grants

(a)	Grantor	Grant Name	Grant Purpose	Term of Grant	Grant Award		Grant Receipts		Grant To Capital Grants		Grant Deferred	Grant Accrued	Grant Income	Type	Expenditure in the period
					€	€	€	€	€	€					
	H.S.E.	Mid West and City	Operational	2023	235,211	235,211	-	-	-	-	-	-	235,211	Restricted	227,519
	H.S.E.	Inflation Fund	Operational	2023	-	10,205	-	(10,205)	-	-	-	-	-	Restricted	-
	H.S.E.	Mid West and City	Operational	2023	12,161	12,161	-	-	-	-	-	-	12,161	Restricted	12,161
	H.S.E.	Pay Restoration	Operational	2023	13,228	13,228	-	-	-	-	-	-	13,228	Restricted	13,228
										647					
	H.S.E.	Small Grants Treatment & Rehab	Project Costs	2023	34,832	34,832	-	(647)	-	-	-	-	34,832	Restricted	34,832
	H.S.E.		Project Costs	2023	29,365	29,365	-	-	-	-	-	-	29,365	Restricted	29,365
	H.S.E.	Projects	Project Costs	2023	-	-	-	-	23,500	(3,500)	-	-	20,000	Restricted	20,000
	H.S.E.	Community Mobilisation Traveller Health Once Off	Project Costs	2023	-	-	-	-	14,500	-	-	-	14,500	Restricted	14,500
	H.S.E.	Hidden Harm	Project Costs	2023	27,500	27,500	-	-	4,000	-	-	-	4,000	Restricted	4,000
	H.S.E.	LLADT	Project Costs	2023	-	-	-	-	-	-	-	-	27,500	Restricted	27,500
	H.S.E.	Limerick & Clare Education & Training Board -	Project Costs	2023	-	-	-	(1,100)	-	-	-	7,204	6,104	Restricted	6,104

**Mid West Regional Drugs Task Force
Company Limited by Guarantee**

**Notes to the financial statements (continued)
Financial year ended 31 December 2023**

Dept of Children & Youth Affairs	Education, Prevention & Training	Project Costs	2023	80,575	80,575	(2,820)	2,820	80,575 Restricted	80,575
				<u>432,872</u>	<u>443,077</u>	<u>(1,100)</u>	<u>(181)</u>	<u>477,476</u>	<u>469,784</u>

(b) €1,100 of LLADT finding from the H.S.E. was expended on the purchase of computer equipment during the year.

(c) Employees

No of Employees

Employee Benefits
€60,000 and greater

None

Total Employer Pension Contributions

Nil

(d) Tax Clearance

The company is compliant with relevant circulars, including Circular 44/2006 "Tax Clearance Procedures Grants, Subsidies and Similar Type Payments".

This note is in adherence with the requirements set out in Circular 13/2014 which supercedes Circular 17/2010.

**Mid West Regional Drugs Task Force
Company Limited by Guarantee**

**Notes to the financial statements (continued)
Financial year ended 31 December 2023**

12. Events after the end of the reporting period

There were no significant events affecting the company since the financial year end.

13. Controlling party

The company is controlled by its board of directors.

14. Ethical standards

As a small entity under the provisions of the APB in relation to Ethical Standards we engage our auditor to provide CRO filing and accounts preparation services.

15. Total Funds

	Unrestricted Funds	Restricted Funds	Balance 31st Dec
	€	€	€
At 1 January, 2022	-	84,501	84,501
Transfers between funds	-	-	-
Operating surplus/(deficit) for the year	-	(49,005)	(49,005)
At 31 December 2022 & 1 January, 2023	-	35,495	35,495
Transfers between Funds	-	-	-
Operating surplus/(deficit) for the year	-	7,690	7,690
At 31 December, 2023	-	43,184	43,184

The General Reserve represents the free funds of the charity, which are not designated for particular purposes

16. Approval of financial statements

The board of directors approved these financial statements for issue on 11 April 2024.

**Mid West Regional Drugs Task Force
Company Limited by Guarantee**

The following pages do not form part of the statutory accounts.

**Mid West Regional Drugs Task Force
Company Limited by Guarantee**

**Detailed income & expenditure account
Financial year ended 31 December 2023**

	2023	2022
	€	€
Income		
H.S.E.	396,901	316,804
Limerick and Clare Education & Training Board	80,575	80,575
	<u>477,476</u>	<u>397,379</u>
 Administrative expenses		
Wages and salaries	177,174	150,013
Employer's PRSI contributions	19,502	16,559
Supervision	800	770
Rent Payable	6,000	12,000
Light and heat	1,587	3,041
Materials and Cleaning	1,990	3,633
IT costs	5,434	5,212
Office Supplies & Services	3,690	7,016
Promotion & Advertising	360	524
Training	2,435	2,260
Telephone	6,170	4,877
Meeting Expenses	4,534	1,875
Parking	2,080	2,725
Project Costs	212,140	217,753
Travelling and subsistence	11,343	7,236
Legal and professional	5,626	3,998
Auditors remuneration	4,967	3,797
Bank charges	248	222
General expenses	3,706	2,873
Depreciation of tangible assets	968	924
Capital Grant Released	(968)	(924)
	<u>469,786</u>	<u>446,384</u>
 Surplus/(deficit) for year	<u><u>7,690</u></u>	<u><u>(49,005)</u></u>